Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress

-- Szilárd Kiss, M.D. to present an encore presentation of data from first cohort of the OPTIC phase 1 trial of ADVM-022 in wet AMD --

MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations on the company’s gene therapy programs to be presented at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress in Barcelona, Spain.

Click to view original post